Product Information
TYDEMY 3-0.03-0.451 MG TABLET is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $2.9597 per EA under NDC 68180090473. Its NADAC has been published 130 times since Mar 10, 2021.
FDA first approved this application on Dec 12, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
TYDEMY 3-0.03-0.451 MG TABLET
Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate CalciumManufacturer
Lupin Pharmaceuticals Inc.NDC
68180090473
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205948FDA Approved
12/12/2017
TE Code
AB
On Market Since
11/20/2020
Price Statistics
The NADAC for TYDEMY 3-0.03-0.451 MG TABLET has been published 130 times since Mar 10, 2021, and over the history we have for it it has declined 35.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.9597 per EA |
|---|---|
| All-time high | $4.5983 (Sep 15, 2021) |
| All-time low | $2.9093 (Aug 19, 2026) |
| 52-week high | $3.2819 |
| 52-week low | $2.9093 |
| Median price | $3.2470 |
| Average price | $3.5108 |
| Largest weekly change | -22.1% (Apr 17, 2024) |
| Weeks tracked | 130 |
| Tracking since | Mar 10, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Drospirenone, Ethinyl Estradiol and Levomefolate Calcium and Levomefolate Calcium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TYDEMY 3-0.03-0.451 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TYDEMY 3-0.03-0.451 MG TABLET, manufactured by Lupin Pharmaceuticals Inc., is $2.9597 per EA (NDC 68180090473), effective Sep 30, 2026.
How has the price of TYDEMY 3-0.03-0.451 MG TABLET changed over time?
Over the history we have for it, the NADAC for TYDEMY 3-0.03-0.451 MG TABLET has declined 35.6%. It has been tracked across 130 weekly CMS publications since Mar 10, 2021.
What are the highest and lowest recorded NADAC prices for TYDEMY 3-0.03-0.451 MG TABLET?
Since Mar 10, 2021, the NADAC for TYDEMY 3-0.03-0.451 MG TABLET has ranged from a low of $2.9093 (Aug 19, 2026) to a high of $4.5983 (Sep 15, 2021), with a median of $3.2470 per EA.
Are there cheaper alternatives to TYDEMY 3-0.03-0.451 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TYDEMY 3-0.03-0.451 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TYDEMY 3-0.03-0.451 MG TABLET?
TYDEMY 3-0.03-0.451 MG TABLET (NDC 68180090473) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.